- Home
- ESQ vs GYRE Comparison
ESQ vs GYRE Comparison
Compare ESQ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESQ
- GYRE
- Stock Information
- Founded
- ESQ 2006
- GYRE 2002
- Country
- ESQ United States
- GYRE United States
- Employees
- ESQ N/A
- GYRE N/A
- Industry
- ESQ Commercial Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ESQ Finance
- GYRE Health Care
- Exchange
- ESQ Nasdaq
- GYRE Nasdaq
- Market Cap
- ESQ 886.6M
- GYRE 897.1M
- IPO Year
- ESQ 2017
- GYRE N/A
- Fundamental
- Price
- ESQ $96.14
- GYRE $7.27
- Analyst Decision
- ESQ Hold
- GYRE
- Analyst Count
- ESQ 3
- GYRE 0
- Target Price
- ESQ $103.00
- GYRE N/A
- AVG Volume (30 Days)
- ESQ 149.2K
- GYRE 81.2K
- Earning Date
- ESQ 07-24-2025
- GYRE 08-12-2025
- Dividend Yield
- ESQ 0.72%
- GYRE N/A
- EPS Growth
- ESQ 12.45
- GYRE N/A
- EPS
- ESQ 5.39
- GYRE 0.02
- Revenue
- ESQ $126,841,000.00
- GYRE $100,643,000.00
- Revenue This Year
- ESQ N/A
- GYRE $21.04
- Revenue Next Year
- ESQ $10.72
- GYRE $89.64
- P/E Ratio
- ESQ $18.00
- GYRE $92.27
- Revenue Growth
- ESQ 12.91
- GYRE N/A
- 52 Week Low
- ESQ $54.49
- GYRE $6.11
- 52 Week High
- ESQ $106.11
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ESQ 46.66
- GYRE 44.07
- Support Level
- ESQ $95.85
- GYRE $7.09
- Resistance Level
- ESQ $106.11
- GYRE $7.89
- Average True Range (ATR)
- ESQ 3.56
- GYRE 0.37
- MACD
- ESQ -0.75
- GYRE 0.04
- Stochastic Oscillator
- ESQ 9.52
- GYRE 24.39
About ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.